Par Pharmaceutical begins shipment of generic Flonase

By Elaine Rigoli

Tampa, Fla., Feb. 23 - Par Pharmaceutical Cos. Inc. announced Thursday that it has entered into a supply and distribution agreement with GlaxoSmithKline in the United States to distribute fluticasone propionate aqueous nasal spray, 50 mcg, a full substitution for GlaxoSmithKline's Flonase.

Flonase is a synthetic corticosteroid anti-inflammatory agent. It is indicated for the management of the nasal symptoms of seasonal and perennial allergic and nonallergic rhinitis in adults and pediatric patients four years of age and older.

Annual U.S. sales of Flonase exceed $900 million, according to a company news release. Par began shipping fluticasone propionate aqueous nasal spray on Thursday.

Under the terms of the agreement, Par began shipment of its generic Flonase once another generic version of the drug became available in the United States, the company said.

Par's product will be manufactured by a GlaxoSmithKline subsidiary and GlaxoSmithKline will receive a share of Par's profits.

Par develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. The company is based in Spring Valley, N.Y.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.